Sunday, November 22, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· March 24, 2026

KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF

View original at finance.yahoo.com
“Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase.”
Verbatim excerpt from the source · Yahoo Finance · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The company is gradually expanding into broader non-oncology therapeutic areas such as autoimmune diseases and metabolic disorders

    60% confidence
  • The company is actively advancing cutting-edge modalities including bispecific ADCs, RDCs, iADCs, and DACs

    60% confidence
  • The company has built a robust pipeline of more than 30 drug candidates, with over 10 in the clinical stage

    60% confidence
  • The company will leverage its innovative and differentiated pipeline to deliver high-quality therapeutic solutions for major unmet medical needs worldwide

    60% confidence

Cited in these Via News reports

KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF: Source | Via News | vianews.market